<SEC-DOCUMENT>0001193125-14-133760.txt : 20140407
<SEC-HEADER>0001193125-14-133760.hdr.sgml : 20140407
<ACCEPTANCE-DATETIME>20140407171721
ACCESSION NUMBER:		0001193125-14-133760
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20140401
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140407
DATE AS OF CHANGE:		20140407

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ORTHOFIX INTERNATIONAL N V
		CENTRAL INDEX KEY:			0000884624
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19961
		FILM NUMBER:		14749380

	BUSINESS ADDRESS:	
		STREET 1:		7 ABRAHAM DE VEERSTRAAT
		STREET 2:		CURACAO
		CITY:			NETHERLANDS ANTILLES
		STATE:			P8
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d707892d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, DC 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): April&nbsp;1, 2014 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Orthofix International N.V. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of Registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Cura&ccedil;ao</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>0-19961</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>N/A</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>7 Abraham de Veerstraat</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Cura&ccedil;ao</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>N/A</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: 011-59-99-465-8525 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (<I>see</I> General Instruction A.2. below): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;1.01.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><U>Entry into a Material Definitive Agreement</U>. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amendment No.&nbsp;4 to Matrix Commercialization
Collaboration Agreement with Musculoskeletal Transplant Foundation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Orthofix International N.V. (the &#147;<U>Company</U>&#148;) is
party, through its wholly owned subsidiary, Orthofix Holdings, Inc. (&#147;<U>Orthofix</U>&#148;), to a Matrix Commercialization Collaboration Agreement, dated as of July&nbsp;24, 2008, between Orthofix and Musculoskeletal Transplant Foundation
(&#147;<U>MTF</U>&#148;), as amended by Amendment No.&nbsp;1 thereto dated December&nbsp;15, 2010, Amendment No.&nbsp;2 thereto dated January&nbsp;9, 2012 and Amendment No.&nbsp;3 thereto dated July&nbsp;1, 2013 and effective as of June&nbsp;25,
2013 (as amended, the &#147;<U>Existing&nbsp;Agreement</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Existing Agreement, Orthofix and MTF agreed to
commercialize Trinity Evolution<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and Trinity ELITE&#153; both technologies being allograft matrices with viable cells.&nbsp;Orthofix maintains exclusive marketing rights to Trinity Evolution<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and Trinity ELITE&#153;, and MTF supplies the products, in an allograft tissue form, to customers in accordance with orders received directly from Orthofix.&nbsp;MTF sources, processes and
packages the tissue form and is the sole supplier of Trinity<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Evolution&#153; and Trinity ELITE&#153; to customers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;1, 2014, Orthofix and MTF entered into Amendment No.&nbsp;4 to Matrix Commercialization Collaboration Agreement and Amendment
No.&nbsp;1 to Marketing Representative Agreement (the &#147;<U>Amendment</U>&#148;).&nbsp;Under the Amendment, which is effective as of January&nbsp;1, 2014, Orthofix and MTF have agreed (i)&nbsp;that MTF will initially pay certain administrative
fees payable to integrated delivery networks and/or group purchasing organizations in connection with the Existing Agreement and Orthofix will reimburse MTF (subject to a fee cap) for a percentage of such administrative fees, (ii)&nbsp;MTF will
initially pay the cost of shipping charges and courier fees with respect to delivery of the product under the Existing Agreement and Orthofix will reimburse MTF for a percentage of any charges related to expedited delivery requested by Orthofix for
shipping and courier charges not invoiced to customers, (iii)&nbsp;to amend (a)&nbsp;the calculation of &#147;Marketing Fees&#148; under both the Existing Agreement and a related &#147;Marketing Representative Agreement&#148; between Orthofix and
MTF so that they are based on service fees invoiced (rather than fees received) by MTF, less any documented bad debt adjustments, and (b)&nbsp;the period after which MTF will pay such Marketing Fees to Orthofix, (iv)&nbsp;that MTF will pay to
Orthofix a &#147;true-up&#148; payment with respect to Marketing Fees of approximately $5.9 million in three equal monthly installments commencing on April&nbsp;1, 2014, and (v)&nbsp;that Orthofix will pay to MTF a non-accountable annual charge,
payable on a quarterly basis, of $100,000, to be used by MTF in its discretion to fund research and development activities with respect to the product, or feasibility development work for related new technologies.&nbsp;The foregoing does not
constitute a complete summary of the Amendment, and is qualified in its entirety by reference to the text of the Amendment, which is filed herewith as Exhibits 10.1 and is incorporated herein by reference. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Exhibits </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Amendment No. 4 to Matrix Commercialization Collaboration Agreement, entered into on April&nbsp;1, 2014, by and between Musculoskeletal Transplant Foundation, Inc. and Orthofix Holdings, Inc.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Orthofix International N.V.</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jeffrey M. Schumm</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jeffrey M. Schumm</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Administrative
Officer, General</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Counsel and Corporate Secretary</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: April&nbsp;7, 2014 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:23.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit<BR>No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Description</P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amendment No. 4 to Matrix Commercialization Collaboration Agreement, entered into on April 1, 2014, by and between Musculoskeletal Transplant Foundation, Inc. and Orthofix Holdings, Inc.</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d707892dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT NO. 4 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO
MATRIX COMMERCIALIZATION COLLABORATION AGREEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND AMENDMENT NO. 1 TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MARKETING REPRESENTATIVE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS AMENDMENT NO. 4 TO MATRIX COMMERCIALIZATION COLLABORATION AGREEMENT AND AMENDMENT NO. 1 TO MARKETING REPRESENTATIVE AGREEMENT</B>
(collectively, this &#147;<B><U>Amendment</U></B>&#148;) is dated as of the date of the last signature hereunder and effective as of January&nbsp;1, 2014 (the &#147;<B><U>Amendment Effective Date</U></B>&#148;) by and between Musculoskeletal
Transplant Foundation, Inc., a non-profit corporation formed under the laws of the District of Columbia, and having a principal place of business at 125&nbsp;May Street, Suite 300, Edison, New Jersey 08837 (&#147;<B><U>MTF</U></B>&#148;), and
Orthofix Holdings, Inc., a corporation organized under the laws of the State of Delaware, and having a principal place of business at 3451 Plano Parkway, Lewisville, Texas 75056 (&#147;<B><U>Orthofix</U></B>&#148;) (each, individually, a
&#147;<B><U>Party</U></B>&#148; and, collectively, the &#147;<B><U>Parties</U></B>&#148;).<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>W</U>&nbsp;<U>I</U>&nbsp;<U>T</U>&nbsp;<U>N</U>&nbsp;<U>E</U>&nbsp;<U>S</U>&nbsp;<U>S</U>&nbsp;<U>E</U>&nbsp;<U>T</U>&nbsp;
<U>H</U><U>:</U> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Parties have entered into that certain Matrix Commercialization Collaboration Agreement dated as
of July&nbsp;28, 2008, as amended by that certain Amendment No.&nbsp;1 to Matrix Commercialization Collaboration Agreement dated as of December&nbsp;15, 2010, that certain Amendment No.&nbsp;2 to Matrix Commercialization Collaboration Agreement
dated as of January&nbsp;9, 2012 and that certain Amendment No.&nbsp;3 to Matrix Commercialization Collaboration Agreement dated as of June&nbsp;25, 2013 (collectively, the &#147;<B><U>Matrix Agreement</U></B>&#148;), pursuant to which the Parties
have collaborated on the commercialization of the Matrix (as defined in the Matrix Agreement); and <B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Parties
have further entered into that certain Marketing Representative Agreement dated as of July&nbsp;24, 2012 (the &#147;<B><U>Amniotic Products Agreement</U></B>&#148;) with respect to the marketing of certain dried amniotic membrane-based biomaterial
in various sizes (as more particularly defined under the Amniotic Products Agreement, the &#147;<B><U>Products</U></B>&#148;); and<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS, </B>the Parties desire to supplement and amend their arrangements under each of the Matrix Agreement and the Amniotic Products
Agreement upon the terms and subject to the conditions hereinafter set forth;<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, in consideration of the
foregoing premises and mutual covenants contained herein, the Parties agree as follows:<B> </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SUPPLEMENTAL ARRANGEMENTS AND AMENDMENTS</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>A. <B><U>Integrated Delivery Networks / Group Purchasing Organizations</U></B> The Parties agree that, from and after the Amendment
Effective Date and in the event of sales to integrated delivery networks and/or group purchasing organizations of the Matrix pursuant to the Matrix Agreement, and of Products pursuant to the Amniotic Products Agreement, MTF shall initially pay the
administrative fees payable to such organizations attributable, respectively, to the Matrix <B> </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>
</B>and the Products. With respect to all such administrative fees actually paid by MTF on sales of the Matrix and the Products under its agreements with integrated delivery networks and/or group
purchasing organizations (such fees, unless otherwise agreed in writing by the Parties, solely to the extent they do not exceed three and one-half percent (3.5%)&nbsp;of the Service Fees for the applicable units of the Matrix or the Products under
the Matrix Agreement and the Amniotic Products Agreement, respectively, are referred to as &#147;<B><U>Administrative Fees</U></B>&#148;): <B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Orthofix shall reimburse MTF for a percentage of such Administrative Fees so paid with respect to the Matrix, that is equal
to the percentage of the applicable Service Fees that is used to calculate the Marketing Fee for the Matrix under Section&nbsp;5.2 of the Matrix Agreement, without regard to any applicable Minimum Service Fee (as defined in the Matrix Agreement);
and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Orthofix shall reimburse MTF for a percentage of such Administrative Fees so paid with respect to the Products,
that is equal to the percentage of the applicable Service Fees that is used to calculate the Marketing Fee for the Products under Section&nbsp;5.2 of the Amniotic Products Agreement, without regard to any applicable Minimum Service Fee (as defined
in the Amniotic Products Agreement) (the percentage described in clause (i)&nbsp;or (ii)&nbsp;immediately preceding, as applicable, the &#147;<U><B>Marketing Fee Percentage</B></U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accordingly, together with the last Monthly Statement (as defined under the Matrix Agreement and the Amniotic Products Agreement, respectively) of each
calendar quarter, MTF shall provide a summary of all such Administrative Fees paid by MTF during the immediately preceding calendar quarter, together with reasonable supporting documentation therefor on a product-by-product and payee-by-payee basis.
In addition, together with each Monthly Statement, MTF shall provide to Orthofix an invoice for an amount equal to the product obtained by multiplying (x)&nbsp;the amount of such Administrative Fees paid by MTF during the applicable month by
(y)&nbsp;the applicable Marketing Fee Percentage. Orthofix shall pay such amount to MTF within forty-five (45)&nbsp;days after receipt of such invoice. In the event Orthofix fails timely to pay any such amounts, MTF may, in addition to any other
remedies available to it, assess interest at a rate of one percent (1%)&nbsp;per month on all such unpaid amounts. MTF shall indemnify, defend, and hold harmless Orthofix from and against all Damages (as defined under the Matrix Agreement and the
Amniotic Products Agreement, respectively) arising out of the payment of any Administrative Fees by MTF to any integrated delivery network and/or group purchasing organization in violation of applicable law, subject, however, to the same procedures
applicable to indemnification and limitations thereon as set forth in the Matrix Agreement and the Amniotic Products Agreement, respectively (such provisions applied, <U>mutatis</U> <U>mutandis</U>). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>B. <B><U>Shipping</U></B>. The Parties agree that, from and after the Amendment Effective Date, MTF shall initially pay the cost of
shipping charges and courier fees with respect to the Matrix and the Products, but if (i)&nbsp;Orthofix has requested in writing that MTF provide expedited delivery or courier service of any shipment of the Matrix or a Product and has approved the
applicable shipping or courier charges, and (ii)&nbsp;less than the entirety of the shipping and courier charges are invoiced to the applicable customer on sales of the Matrix pursuant to the Matrix Agreement, and of Products pursuant to the
Amniotic Products Agreement, then Orthofix shall reimburse MTF for a percentage of such shipping and courier charges not invoiced to customers <B> </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that is equal to the applicable Marketing Fee Percentage. Accordingly, together with each Monthly Statement, MTF shall set forth the amount of all such shipping charges with respect to the Matrix
and the Products that were not invoiced in the amount of the entirety thereof, together with reasonable supporting documentation therefor on a product-by-product basis, and shall provide to Orthofix an invoice for an amount equal to the product
obtained by multiplying (x)&nbsp;the amount of all such shipping charges not invoiced on sales of the Matrix with respect to the applicable month pursuant to the Matrix Agreement, and of Products pursuant to the Amniotic Products Agreement by
(y)&nbsp;the Marketing Fee Percentage then in effect. Orthofix shall pay to MTF within forty-five (45)&nbsp;days after receipt of such invoice. In the event Orthofix fails timely to pay any such amounts, MTF may, in addition to any other remedies
available to it, assess interest at a rate of one percent (1%)&nbsp;per month on all such unpaid amounts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>C. <B><U>Marketing Fee
Calculation and Payment Terms</U></B>. For periods commencing with the Amendment Effective Date, the Marketing Fees under both the Matrix Agreement and the Amniotic Products Agreement shall be (1)&nbsp;calculated based on the total amount of Service
Fees invoiced by MTF (but net of any documented bad debt adjustments for invoices dated after January&nbsp;1, 2014 which MTF has provided reasonable supporting documentation to Orthofix), instead of based on Service Fees received by MTF, and
(2)&nbsp;paid by MTF to Orthofix no later than the fifteenth (15th)&nbsp;day of the second calendar month after the end of the calendar month to which they relate. Accordingly, the Matrix Agreement and the Amniotic Products Agreement are hereby
amended as follows as of the date first above-written:<B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Paragraph (b)&nbsp;of Section&nbsp;4.1 of the Amniotic
Products Agreement is hereby amended by deleting the phrase &#147;fifteen (15)&nbsp;days&#148; contained therein and inserting in lieu thereof the phrase &#147;forty-five (45)&nbsp;days&#148;; Paragraph (b)&nbsp;of Section&nbsp;4.1 of each of the
Matrix Agreement and the Amniotic Products Agreement is hereby amended to insert a reference to &#147;commencing January&nbsp;1, 2014&#148; immediately following the reference to &#147;calendar month&#148;; clause (i)&nbsp;of Paragraph (b)&nbsp;of
Section&nbsp;4.1 of each of the Matrix Agreement and the Amniotic Products Agreement is hereby deleted and the following inserted in lieu thereof: &#147;(i) all Services Fees invoiced by MTF (but net of any documented bad debt adjustments for
invoices dated after January&nbsp;1, 2014 which MTF has provided reasonable supporting documentation to Orthofix),&#148;; clauses (ii)&nbsp;and (iv)&nbsp;of Paragraph (b)&nbsp;of Section&nbsp;4.1 of each of the Matrix Agreement and the Amniotic
Products Agreement are hereby deleted; and clauses (iii)&nbsp;and (v)&nbsp;of Paragraph (b)&nbsp;of Section&nbsp;4.1 of each of the Matrix Agreement and the Amniotic Products Agreement are hereby re-designated, respectively, as clauses (ii)&nbsp;and
(iii); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) the first sentence of Section&nbsp;5.2 of the Amniotic Products Agreement is hereby amended by inserting a
reference to &#147;second&#148; immediately prior to the reference to &#147;previous&#148;; and the first sentence of Section&nbsp;5.2 of each of the Matrix Agreement and the Amniotic Products Agreement is hereby amended: (x)&nbsp;to insert a
reference to &#147;commencing January&nbsp;1, 2014&#148; immediately following the reference to &#147;calendar month&#148;; and (y)&nbsp;by deleting the phrase &#147;Service Fees received by MTF&#148; and inserting in lieu thereof the phrase
&#147;Services Fees invoiced by MTF (but net of any documented bad debt adjustments for invoices dated after January&nbsp;1, 2014which MTF has provided reasonable supporting documentation to Orthofix)&#148;; and </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Section&nbsp;5.2 of each of the Matrix Agreement and the Amniotic Products
Agreement is hereby further amended by adding the following statement immediately after the third sentence: &#147;For clarity, payment of the Marketing Fee will be made by wire transfer no later than the fifteenth (15<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP>)&nbsp;day of the second calendar month after the end of the calendar month in which the applicable Service Fees were invoiced (e.g., the Marketing Fee with respect to Service Fees invoiced in
January will be due no later than March&nbsp;15).&#148;; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">it being acknowledged and agreed that the provisions of Sections 4.1(b) and 5.2 of each of the
Matrix Agreement and the Amniotic Products Agreement will have no further application with respect to calendar months prior to the Amendment Effective Date; provided, however, that, MTF shall pay to Orthofix a &#147;true-up&#148; payment of
$5,930,976.13, reflecting the Marketing Fees that, giving retroactive effect to such amendments with respect to calendar months prior to the end of calendar year 2013, would have been owed in respect of Service Fees invoiced by MTF (but net of any
documented bad debt adjustments for invoices dated prior to January&nbsp;1, 2014 which MTF has provided reasonably supporting documentation to Orthofix) and not received by MTF. Such true-up payment will be net of all payments of Marketing Fees made
by MTF to Orthofix subsequent to the Amendment Effective Date, relating to amounts received prior to the end of calendar year 2013. The true-up payment will be made in three equal installments on, respectively, April&nbsp;1, 2014 of $1,976,992.04,
May&nbsp;1, 2014 of $1,976,992.04 and June&nbsp;1, 2014 of $1,976,992.04. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>D. <B><U>Non-Accountable R&amp;D Charge.</U></B>
Following the Amendment Effective Date and through the Term set forth in the Matrix Agreement, Orthofix shall be obligated to pay to MTF a non-accountable annual charge of One Hundred Thousand Dollars ($100,000), to be used by MTF, in its sole
discretion, to fund research and development activities by MTF with respect to bone growth allograft products containing viable allogeneic stem cells derived from cadavers. Any and all products, technologies and discoveries, other than the Matrix,
developed or discovered as a result of such activities shall constitute &#147;Product Concepts&#148; subject to Section&nbsp;6.2(a) of the Matrix Agreement, and shall be subject to the right of first offer, right of first refusal and other terms and
conditions set forth in Section&nbsp;6.2 of the Matrix Agreement. As requested by the Steering Committee from time to time, MTF shall provide a summary of and reasonable documentation regarding the activities conducted by MTF pursuant to this
Paragraph D and the results of such activities. Accordingly, contemporaneously with the date of this Amendment and thereafter at the beginning of each calendar quarter during the Term of the Matrix Agreement, MTF shall submit to Orthofix an invoice
for a quarterly payment of Twenty Five Thousand Dollars ($25,000), and Orthofix shall pay such amount to MTF within forty-five (45)&nbsp;days after receipt of such invoice. In the event Orthofix fails timely to pay any such amounts, MTF may, in
addition to any other remedies available to it, assess interest at a rate of one percent (1%)&nbsp;per month on all such unpaid amounts.<B> </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>MISCELLANEOUS</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>A. <B><U>Accrued Obligations</U></B>. Expiration or termination of the Matrix Agreement and the Amniotic Products Agreement, or either
of them, or any obligation to deliver Monthly Statements, shall not extinguish any right of MTF under Article I, Sections A through C hereof with respect to quantities of the Matrix and Products sold prior to the effective date of such expiration or
termination.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>B. <B><U>NuVasive License</U></B>. Orthofix hereby represents, warrants and confirms to MTF that it has
complied with the provisions of the NuVasive License (as defined in the Matrix Agreement), including without limitation, Section&nbsp;3.2 thereof, with respect to this Amendment.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>C. <B><U>Original Agreements</U></B>. The provisions hereof shall in all respects supplement and amend the terms of the Matrix
Agreement and the Amniotic Products Agreement, respectively. As supplemented and amended hereby, each of the Matrix Agreement and the Amniotic Products Agreement shall remain in full force and effect.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>D. <B><U>Counterparts</U></B>. This Amendment may be executed in counterparts, each of which shall be deemed to be an original, and all
of which taken together will constitute one and the same instrument.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[Signature page follows] </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have caused this Amendment to be executed and delivered as
of the date first written above.<B> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MUSCULOSKELETAL TRANSPLANT</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>FOUNDATION, INC.</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><B>ORTHOFIX HOLDINGS, INC.</B></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Bruce Stroever</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Emily Buxton</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">President &amp; Chief Executive Officer</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">4/1/14</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Date:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">4/1/14</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
